Analysts expect SAB Biotherapeutics, Inc. to report revenue of 0.00 for Q3 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 100,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 135,621.51 | 121,125.18 | 130,854.42 | 129,401.66 | 101,954.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4,978.41 | 9,643.82 | 1.91 M | 2.09 M | ||||||||||
| Low Estimate | 114,348.09 | 110,783.22 | 110,101.82 | 111,497.10 | 93,360.57 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4,368.57 | 8,525.52 | 1.77 M | 1.86 M | ||||||||||
| Consensus Estimate | 124,984.80 | 115,954.20 | 120,478.12 | 120,449.38 | 97,657.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4,673.49 | 9,084.67 | 1.84 M | 1.98 M |
Analysts expect SAB Biotherapeutics, Inc. to report earnings per share of -0.25 for Q3 26, against a range of -0.26 to -0.24. The most recent reported quarter, Q2 26, came in at -0.28, a 6.7% beat against the -0.30 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.12 | -1.23 | -0.56 | -1.09 | -0.21 | -0.27 | -0.35 | -0.28 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -1.10 | -1.16 | -0.91 | -0.69 | -0.45 | -0.21 | -0.18 | -0.28 | -0.24 | -0.23 | -0.20 | -0.21 | 0.06 | -0.02 | -0.29 | -0.38 | ||||||||||
| Low Estimate | -1.24 | -1.28 | -1.09 | -0.83 | -0.51 | -0.23 | -0.22 | -0.32 | -0.26 | -0.27 | -0.22 | -0.23 | 0.06 | -0.02 | -0.31 | -0.40 | ||||||||||
| Consensus Estimate | -1.17 | -1.22 | -1.00 | -0.76 | -0.48 | -0.22 | -0.20 | -0.30 | -0.25 | -0.25 | -0.21 | -0.22 | 0.06 | -0.02 | -0.30 | -0.39 |
Pull Wall Street consensus for SAB Biotherapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=SABS&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "SABS", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=SABS&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();